Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.
Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. Manasanch EE, et al. Among authors: feng l. Blood Adv. 2019 Aug 13;3(15):2400-2408. doi: 10.1182/bloodadvances.2019000300. Blood Adv. 2019. PMID: 31405950 Free PMC article.
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Manasanch EE, et al. Among authors: feng l. Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1. Lancet Haematol. 2018. PMID: 30501870 Clinical Trial.
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Tabchi S, et al. Among authors: feng l. Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):560-569. doi: 10.1016/j.clml.2019.05.001. Epub 2019 May 17. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31201134 Free PMC article. Review.
Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.
Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Manasanch EE, et al. Among authors: feng l. Haematologica. 2020 May;105(5):e242-e245. doi: 10.3324/haematol.2019.225375. Epub 2019 Aug 14. Haematologica. 2020. PMID: 31413094 Free PMC article. Clinical Trial. No abstract available.
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. Lee HC, et al. Among authors: feng l. Blood Cancer J. 2019 Oct 1;9(10):80. doi: 10.1038/s41408-019-0240-6. Blood Cancer J. 2019. PMID: 31575851 Free PMC article. Clinical Trial. No abstract available.
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.
Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Kunacheewa C, et al. Among authors: feng l. Clin Lymphoma Myeloma Leuk. 2020 May;20(5):e221-e238. doi: 10.1016/j.clml.2020.01.001. Epub 2020 Jan 15. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32037287 Free PMC article. Clinical Trial.
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up.
Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Manasanch EE, et al. Among authors: feng l. Blood Cancer J. 2021 Feb 8;11(2):17. doi: 10.1038/s41408-021-00419-1. Blood Cancer J. 2021. PMID: 33563896 Free PMC article. No abstract available.
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma.
Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS. Nastoupil LJ, et al. Among authors: feng l. Blood Adv. 2022 Feb 22;6(4):1143-1151. doi: 10.1182/bloodadvances.2021006240. Blood Adv. 2022. PMID: 35015819 Free PMC article. Clinical Trial.
11,143 results
You have reached the last available page of results. Please see the User Guide for more information.